- Report
- December 2023
- 200 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- September 2022
- 30 Pages
Global
From €3142EUR$3,250USD£2,700GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €3142EUR$3,250USD£2,700GBP
- Report
- August 2022
- 161 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- January 2022
- 419 Pages
Global
From €9184EUR$9,500USD£7,894GBP
- Report
- December 2020
- 60 Pages
Global
From €3142EUR$3,250USD£2,700GBP
- Report
- July 2019
Global
From €967EUR$1,000USD£831GBP
- Drug Pipelines
- April 2021
- 64 Pages
Global
€21268EUR$22,000USD£18,280GBP
- Report
- February 2018
- 23 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Drug Pipelines
- February 2018
- 23 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- February 2018
- 680 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Drug Pipelines
- July 2022
- 71 Pages
Global
From €6762EUR$6,995USD£5,812GBP
- Report
- April 2023
- 109 Pages
Global
€3384EUR$3,500USD£2,908GBP
- Drug Pipelines
- June 2021
- 95 Pages
Global
From €1933EUR$2,000USD£1,662GBP
Fasenra is a biologic drug used to treat severe asthma and chronic obstructive pulmonary disease (COPD). It is a monoclonal antibody that works by targeting and blocking the action of interleukin-5 (IL-5), a cytokine that plays a role in the inflammation associated with these conditions. It is administered as an injection under the skin, and is typically used in combination with other asthma and COPD medications.
Fasenra is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is currently marketed by AstraZeneca, and is available in the United States, Canada, and several other countries.
The Fasenra market is highly competitive, with several other biologic drugs available to treat severe asthma and COPD. These include GlaxoSmithKline's Nucala, Teva's Cinqair, and Novartis' Xolair. Other companies in the market include Sanofi, Regeneron, and Biogen. Show Less Read more
